ArticleFrontiers in pharmacology2023
To explore the effect of kaempferol on non-small cell lung cancer based on network pharmacology and molecular docking.
Article in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 14 citations in OpenAlex.
- Molecular Mechanisms of the Anticancer Activity of the Flavonoid Kaempferol: A Comprehensive Review.Journal of cancer prevention · 2026Review
- Oxidative stress-induced endothelial dysfunction drives mechanical and infectious lung injury: Therapeutic potential of kaempferol in males.Redox biology · 2026Article
- The potential utility of in-silico approach in identifying phytochemicals against various targets for the management of lung cancer.Discover oncology · 2026Review
- KANPM-DTA: improving drug-target affinity prediction with Kolmogorov-Arnold networks and pretrained models.Briefings in bioinformatics · 2026Article
- Bibliometric analysis of current trends and emerging patterns in the application of nanomaterials for non-small cell lung cancer.Discover oncology · 2025Article
- Combination of RNA-sequencing data analysis, network pharmacology, molecular docking techniques to investigate the mechanism of Prunella vulgaris L. in the treatment of non-small cell lung cancer.Discover oncology · 2025Article
- Flavonoids in the Treatment of Non-small Cell Lung Cancer via Immunomodulation: Progress to Date.Molecular diagnosis & therapy · 2025Review
- Advances in research on the effects of medicinal and edible substances on lung cancer: an updated review.Frontiers in pharmacology · 2025Review
- Screening of Hub Genes and Therapeutic Drugs in Cervical Cancer Using Integrated Bioinformatics Analysis.Journal of Cancer · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-small cell lung cancer (NSCLC) is a common pathological type of lung cancer, which has a serious impact on human life, health, psychology and life. At present, chemotherapy, targeted therapy and other methods commonly used in clinic are prone to drug resistance and toxic side effects. Natural extracts of traditional Chinese medicine (TCM) have attracted wide attention in cancer treatment because of their small toxic and side effects. Kaempferol is a flavonoid from natural plants, which has been proved to have anticancer properties in many cancers such as lung cancer, but the exact molecular mechanism is still unclear. Therefore, on the basis of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.